RhoVac 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Lars Hedbys

최고 경영자

SEK 191.6k

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO

Lars Hedbys (65 yo)

less than a year

테뉴어

SEK 191,610

보상

Mr. Lars Hedbys, Ph. D., served as Director at Hamlet Pharma AB (publ) until 2022. He serves as Independent Chairman of the Board of Directors at Scandinavian ChemoTech AB (publ) since 2020. He serves as D...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lars Hedbys	Acting CEO & Director	8yrs	SEK 191.61k	데이터 없음
Per Straten	Scientific Advisor & Co-Founder	no data	데이터 없음	데이터 없음
Lars Hockenstrom	Director	3yrs	SEK 191.61k	데이터 없음
Cristina Glad	Director	8yrs	SEK 160.69k	데이터 없음
Gunnar Gardemyr	Chairman	5yrs	SEK 383.22k	데이터 없음
Georg Holländer	Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Anne Ridley	Member of Scientific Advisory Board	2.9yrs	데이터 없음	데이터 없음
Per-Anders Abrahamsson	Scientific advisor	no data	데이터 없음	데이터 없음
Klaus Brasso	Scientific Advisor	no data	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: RHOVAC 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

RhoVac 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

No independent directors

Recent updates

Chosa ApS completed the acquisition of RhoVac AB (NGM:RHOVAC) from M2 Asset Management AB (publ) and others in a reverse merger transaction.

RhoVac AB to Report Fiscal Year 2022 Results on Feb 10, 2023

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB to Report Q3, 2022 Results on Nov 11, 2022

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

RhoVac AB to Report Q2, 2022 Results on Aug 26, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint

Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers

No independent directors

RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac AB Announces Another Clean Interim Safety Review of Clinical Phase IIb Study in Prostate Cancer

RhoVac's Market Research Shows Great Potential for A Cancer Vaccine Preventing Recurrence of Metastatic Disease in Multiple Cancers

Rhovac Announces the Completion of Patient Recruitment for the Bravac Clinical Phase Iib Study of Rv001 in Prostate Cancer

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

RhoVac AB Receives Approval to Initiate a Long-Term Follow-Up of Clinical Phase I/II Patients

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Rhovac AB Announces the Initiation of First New US Clinic in Company's Phase IIb Study

New 90-day low: kr21.00

Global Covid-19 Vaccination Roll-Out Causes Delay to Rhovac's Phase IIb Study

RhoVac AB Announces First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

New 90-day high: kr21.15

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Rhovac AB Announces That Positive Results from Rhovac's Clinical Phase I/Ii Study Published in Journal of Immunotherapy of Cancer

New 90-day low: kr16.44

RhoVac AB Announces Covid-19 pandemic affecting RhoVac's clinical phase IIb study

New 90-day high: kr20.65

RhoVac AB Announces First Patient in Treatment in Rhovac's Clinical Phase IIb Study in Sweden

RhoVac AB to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr16.98

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령